Nuvalent (NASDAQ:NUVL) Azioni

NUVALENT INC-A

Nuvalent

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Nuvalent Inc

Press Releases

Nuvalent to Participate in Upcoming March Investor Conferences

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025

Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Nuvalent to Present Trial in Progress Posters for the ALKAZAR Trial of Neladalkib and HEROEX-1 Trial of NVL-330 at the 2025 American Society of Clinical Oncology Annual Meeting

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Earnings

Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results

Nuvalent Appoints Christy Oliger to Board of Directors

Smart Money is Quietly Loading Up On This $160M Oncology Stock — Is Nuvectis Pharma 
 the Next Breakout Biotech? (NASDAQ: NVCT)

Nuvalent Announces Timing of Pivotal Data for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC from ARROS-1 Clinical Trial of Zidesamtinib

Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

NUVL

NVCT

SMMT

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

BridgeBio Pharma

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Caris Life Sciences

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exact Sciences Corporation - Common Stock

Exact Sciences

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Krystal Biotech

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Metsera

Vaxcyte

PTC Therapeutics

Avidity Biosciences

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Baird

Leerink Partners

HC Wainwright & Co.

BMO Capital

Comments

Nuvalent

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO